Intraocular pressure changes related to intravitreal injections of ranibizumab: Analysis of pseudophakia and glaucoma subgroup

International Ophthalmology

Volumn 35, Issue 4, 2014, Pages 541-547

  Demirel, Sibel ^a   Yanik, Ozge ^a   Batioglu, Figen ^a   Ozmert, Emin ^a  

^a ANKARA UNIVERSITY   (Turkey)

Author keywords

Glaucoma; Intraocular pressure; Pseudophakia; Ranibizumab

Indexed keywords

ANTIGLAUCOMA AGENT; RANIBIZUMAB; ANGIOGENESIS INHIBITOR;

ADULT; AGE RELATED MACULAR DEGENERATION; AGED; ARTICLE; BIOMICROSCOPY; CAPSULOTOMY; CONTROLLED STUDY; DIABETIC MACULAR EDEMA; DIABETIC RETINOPATHY; FEMALE; FLUORESCENCE ANGIOGRAPHY; GLAUCOMA; GONIOSCOPY; HUMAN; INTRAOCULAR HYPERTENSION; INTRAOCULAR PRESSURE; MACULAR EDEMA; MAJOR CLINICAL STUDY; MALE; OPHTHALMIC NEODYMIUM YAG LASER; PSEUDOPHAKIA; RETINA VEIN OCCLUSION; RETROSPECTIVE STUDY; RISK FACTOR; SPECTRAL DOMAIN OPTICAL COHERENCE TOMOGRAPHY; VISUAL ACUITY; VISUAL ACUITY CHART; COMPLICATION; DRUG EFFECTS; INTRAVITREAL DRUG ADMINISTRATION; MACULAR DEGENERATION; MIDDLE AGED; OCULAR HYPERTENSION; OCULOPLETHYSMOGRAPHY; PATHOPHYSIOLOGY; PHYSIOLOGY; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; ANGIOGENESIS INHIBITORS; FEMALE; GLAUCOMA; HUMANS; INTRAOCULAR PRESSURE; INTRAVITREAL INJECTIONS; MACULAR DEGENERATION; MALE; MIDDLE AGED; OCULAR HYPERTENSION; PSEUDOPHAKIA; RANIBIZUMAB; RETROSPECTIVE STUDIES; TONOMETRY, OCULAR;

EID: 84983032356     PISSN: 01655701     EISSN: 15732630     Source Type: Journal    
DOI: 10.1007/s10792-014-9981-1     Document Type: Article

References (33)

1. Aiello LP, Avery RL, Arrigg PG et al (1994) Vascular endothelial growth factor in ocular fluid of patients with diabetic retinopathy and other retinal disorders. N Engl J Med 331(22):1480–1487
2. Ciulla TA, Rosenfeld PJ (2009) Antivascular endothelial growth factor therapy for neovascular age-related macular degeneration. Curr Opin Ophthalmol 20(3):158–165
3. Ciulla TA, Rosenfeld PJ (2009) Anti-vascular endothelial growth factor therapy for neovascular ocular diseases other than age-related macular degeneration. Curr Opin Ophthalmol 20(3):166–174
4. Cohen MH, Gootenberg J, Keegan P, Pazdur R (2007) FDA drug approval summary: bevacizumab plus FOLFOX4 as second-line treatment of colorectal cancer. Oncologist 12(3):356–361
5. Falkenstein IA, Cheng L, Freeman WR (2007) Changes of intraocular pressure after intravitreal injection of bevacizumab (avastin). Retina 27(8):1044–1047
6. Bakri SJ, Pulido JS, McCannel CA, Hodge DO, Diehl N, Hillemeier J (2009) Immediate intraocular pressure changes following intravitreal injections of triamcinolone, pegaptanib, and bevacizumab. Eye 23(1):181–185
7. Gismondi M, Salati C, Salvetat ML, Zeppieri M, Brusini P (2009) Short-term effect of intravitreal injection of Ranibizumab (Lucentis) on intraocular pressure. J Glaucoma 18(9):658–661
8. Hollands H, Wong J, Bruen R, Campbell RJ, Sharma S, Gale J (2007) Short-term intraocular pressure changes after intravitreal injection of bevacizumab. Can J Ophthalmol 42(6):807–811
9. Kim JE, Mantravadi AV, Hur EY, Covert DJ (2008) Shortterm intraocular pressure changes immediately after intravitreal injections of anti-vascular endothelial growth factor agents. Am J Ophthalmol 146(6):930–934
10. Bakri SJ, McCannel CA, Edwards AO, Moshfeghi DM (2008) Persisent ocular hypertension following intravitreal ranibizumab. Graefes Arch Clin Exp Ophthalmol 246(7):955–958
11. Good TJ, Kimura AE, Mandava N, Kahook MY (2011) Sustained elevation of intraocular pressure after intravitreal injections of anti-VEGF agents. Br J Ophthalmol 95(8): 1111–1114
12. Mathalone N, Arodi-Golan A, Sar S et al (2012) Sustained elevation of intraocular pressure after intravitreal injections of bevacizumab in eyes with neovascular age-related macular degeneration. Graefes Arch Clin Exp Ophthalmol 250(10):1435–1440
13. Tseng JJ, Vance SK, Della Torre KE et al (2012) Sustained increased intraocular pressure related to intravitreal antivascular endothelial growth factor therapy for neovascular age-related macular degeneration. J Glaucoma 21(4): 241–247
14. Loukianou E, Brouzas D, Apostolopoulos M (2011) Sustained ocular hypertension following intravitreal injections of 0.5 mg/0.05 ml ranibizumab. Int Ophthalmol 31(3): 211–213
15. Adelman RA, Zheng Q, Mayer HR (2010) Persistent ocular hypertension following intravitreal bevacizumab and ranibizumab injections. J Ocul Pharmacol Ther 26(1):105–110
16. Bakri SJ, Ekdawi NS (2008) Intravitreal silicone oil droplets after intravitreal drug injections. Retina 28(7):996–1001
17. Freund KB, Laud K, Eandi CM, Spaide RF (2006) Silicone oil droplets following intravitreal injection. Retina 26(6): 701–703
18. Kahook MY, Liu L, Ruzycki P et al (2010) High-molecularweight aggregates in repackaged bevacizumab. Retina 30(6):887–892
19. Sniegowski M, Mandava N, Kahook MY (2010) Sustained intraocular pressure elevation after intravitreal injection of bevacizumab and ranibizumab associated with trabeculitis. Open Ophthalmol J 4:28–29
20. Hayashi K, Hayashi H, Nakao F, Hayashi F (2000) Changes in anterior chamber angle width and depth after intraocular lens implantation in eyes with glaucoma. Ophthalmology 107(4):698–703
21. Kurimoto Y, Park M, Sakaue H, Kondo T (1997) Changes in the anterior chamber configuration after small-incision cataract surgery with posterior chamber intraocular lens implantation. Am J Ophthalmol 124(6):775–780
22. Pereira FA, Cronemberger S (2003) Ultrasound biomicroscopic study of anterior segment changes after phacoemulsification and foldable intraocular lens implantation. Ophthalmology 110(9):1799–1806
23. Adelman RA, Zheng Q, Mayer HR (2010) Persistent ocular hypertension following intravitreal bevacizumab and ranibizumab injections. J Ocul Pharmacol Ther 26(1):105–110
24. Hoang QV, Mendonca LS, Della Torre KE, Jung JJ, Tsuang AJ, Freund KB (2012) Effect on intraocular pressure in patients receiving unilateral intravitreal anti-vascular endothelial growth factor injections. Ophthalmology 119(2):321–326
25. Rosenfeld PJ, Brown DM, Heier JS et al (2006) Ranibizumab for neovascular age-related macular degeneration. N Engl J Med 355(14):1419–1431
26. Brown DM, Kaiser PK, Michels M et al (2006) Ranibizumab versus verteporfin for neovascular age-related macular degeneration. N Engl J Med 355(14):1432–1444
27. Drance SM (1960) The significance of the diurnal tension variations in normal and glaucomatous eyes. Arch Ophthalmol 64:494–501
28. Cho YK (2008) Early intraocular pressure and anterior chamber depth changes after phacoemulsification and intraocular lens implantation in nonglaucomatous eyes. Comparison of groups stratified by axial length. J Cataract Refract Surg 34(7):1104–1109
29. Issa SA, Pacheco J, Mahmood U, Nolan J, Beatty S (2005) A novel index for predicting intraocular pressure reduction following cataract surgery. Br J Ophthalmol 89(5):543–546
30. Kerimoglu H, Ozturk BT, Bozkurt B, Okka M, Okudan S (2011) Does lens status affect the course of early intraocular pressure and anterior chamber changes after intravitreal injection? Acta Ophthalmol 89(2):138–142
31. Arikan G, Osman Saatci A, Hakan Oner F (2011) Immediate intraocular pressure rise after intravitreal injection of ranibizumab and two doses of triamcinolone acetonide. Int J Ophthalmol 4(4):402–405
32. Ge J, Wand M, Chiang R, Paranhos A, Shields MB (2000) Long-term effect of Nd:YAG laser posterior capsulotomy on intraocular pressure. Arch Ophthalmol 118(10): 1334–1337
33. Jahn CE, Emke M (1996) Long-term elevation of intraocular pressure after neodymium: YAG laser posterior capsulotomy. Ophthalmologica 210(2):85–89